pre-IPO PHARMA

COMPANY OVERVIEW

AELIX Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be included in cure/eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, the Catalan public-private consortium conducting cutting-edge research in this field. AELIX holds a worldwide, exclusive license for the development and commercialization of the HTI immunogen. The company was incorporated in November 2015 and completed an €11.5M ($12.5M) Series A funding shortly thereafter. For more information, please, visit www.aelixtherapeutics.com.


LOCATION

  • Barcelona, , Spain

  • THERAPEUTIC AREAS

  • Autoimmune Disease

  • WEBSITE

    https://www.aelixtherapeutics.com/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    caixa-capital-risc jjdc ysios-capital ysios-capital


    PRESS RELEASES


    Oct 18, 2018

    AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure


    For More Press Releases


    Google Analytics Alternative